New cocktail of drugs aims to shrink Hard-to-Treat abdominal tumors
NCT ID NCT07268677
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding pirfenidone and sintilimab to standard chemotherapy can shrink tumors in 30 people with colorectal cancer that has spread to the lining of the abdomen. Participants will receive the drug combination before any other treatment. The study will first check if enough tumors respond; if too few do, the trial will stop early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pirfenidone, sintilimab, oxaliplatin, capecitabine
What this could lead to
If this combination works, it could offer a new treatment option for people with colorectal cancer that has spread to the lining of the abdomen, potentially shrinking tumors before surgery.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug combination may cause side effects, and there is no guarantee it will be more effective than standard chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.